Download PDF
CC BY-NC-ND 4.0 · Indian J Plast Surg 2011; 44(01): 124-126
DOI: 10.1055/s-0039-1699491
Commentary
Association of Plastic Surgeons of India

Soluble CD 163: A novel biomarker

Rajeev B. Ahuja
Department of Burns, Plastic, Maxillofacial, and Microvascular Surgery, Lok Nayak Hospital and associated Maulana Azad Medical College, New Delhi, India
› Author Affiliations
Further Information

Publication History

Publication Date:
31 December 2019 (online)

Also available at
  PDF Download Permissions and Reprints
 

  • REFERENCES

  • 1 Gaïni S, Pedersen SS, Koldkaer OG, Pedersen C, Moestrup SK, Møller HJ. New immunological serum markers in bacteraemia: Anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis. Clin Exp Immunol 2008;151:423-31.
  • 2 Fang XM, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999;27:1330-4.
  • 3 Holmes CL, Russell JA, Walley KR. Genetic Polymorphisms in Sepsis and Septic Shock-Role in Prognosis and Potential for Therapy. Chest 2003;124:1103-15.
  • 4 Alistair GS, Philip MB, Hewitt JR. Early diagnosis of neonatal sepsis. Pediatrics 1980;65:1036-41.
  • 5 Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-8.
  • 6 Moestrup SK, Moller HJ. CD163: A regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004;36:347-54.
  • 7 Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bächli E, Fehr J, et al.. Soluble hemoglobin–haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol 2005;74:6-10.
  • 8 Aristoteli LP, Møller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006;184:342-7.
  • 9 Moller HJ, Aerts H, Gronbaek H, Peterslund NA, Hyltoft Petersen P, Hornung N, et al.. Soluble CD163: A marker molecule for monocyte/macrophage activity in disease. Scand J Clin Lab Invest Suppl 2002;237:29-33.
  • 10 Moller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 2004;72:135-9.
  • 11 Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:965-71.
  • 12 Moller HJ, Nielsen MJ, Bartram J, Dick MC, Height SE, Moestrup SK, et al.. Soluble CD163 levels in children with sickle cell disease. Brit J Haematol 2011;153:105-10.
  • 13 Moller HJ, Moestrup SK, Weis N, Wejse C, Nielsen, H, Pedersen SS, et al.. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit Care Med 2006;34:2561-6.
  • 14 Gaïni S, Koldkjaer OG, Pedersen SS, Pedersen C, Moestrup SK, Møller HJ. Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections. APMIS 2006;114:103-11.
  • 15 ACCP/SCCM Consensus Conference Committee. Definition for sepsis and organ failure, and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;2:864-74.